[{"id":"382f094f-2c2c-4bea-884f-f64a47d2d877","acronym":"","url":"https://clinicaltrials.gov/study/NCT01097304","created_at":"2021-01-18T04:20:21.441Z","updated_at":"2025-02-25T13:59:48.726Z","phase":"Phase 2","brief_title":"Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia","source_id_and_acronym":"NCT01097304","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MKI67","pipe":"","alterations":" ","tags":["MKI67"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2017-12-19"},{"id":"b31d8b74-74fb-4cfc-bc6e-3594ba487e7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01263145","created_at":"2021-01-18T05:05:52.987Z","updated_at":"2024-07-02T16:37:18.429Z","phase":"Phase 1","brief_title":"MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer","source_id_and_acronym":"NCT01263145","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MKI67","pipe":"","alterations":" ","tags":["MKI67"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • MK-2206"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/05/2011","start_date":" 01/05/2011","primary_txt":" Primary completion: 10/19/2012","primary_completion_date":" 10/19/2012","study_txt":" Completion: 10/19/2012","study_completion_date":" 10/19/2012","last_update_posted":"2017-08-25"}]